US Pharma MarketingWhat’s the status of House lawmakers’ bill on China biotech restrictions?
BINSA, a bipartisan bill restricting US biotech deals with Chinese firms, is in limbo after failing to advance via the House Rules Committee. Sponsors include Reps. Moolenaar and Dingell. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure…
After setting the industry ablaze last month, a bipartisan bill aimed at restricting US biotech companies from striking deals with Chinese counterparts is in limbo.
The Biotech Investment National ...
Source: Endpoints News